MyFinsight
Home
Blog
About
Contact
Download
Download image
Unrealized gain on
available-for-sale securities
$22K
(144.44%↑ Y/Y)
Comprehensive loss
-$24,176K
(81.59%↑ Y/Y)
Other comprehensive
income (loss)
$17K
(118.09%↑ Y/Y)
Unrealized loss on pension
plans
$5K
(-95.15%↓ Y/Y)
Net loss
-$24,193K
(81.56%↑ Y/Y)
Loss before income
tax
-$23,879K
(81.76%↑ Y/Y)
Income tax provision
$314K
(-5.14%↓ Y/Y)
Change in fair value of
2023 common warrants
-$60,184K
(-230.46%↓ Y/Y)
Interest and other
income, net
$3,922K
(-10.99%↓ Y/Y)
Loss from operations
-$87,985K
(1.31%↑ Y/Y)
Revenue from customers
$2,186K
(554.49%↑ Y/Y)
Total operating
expenses
$90,171K
(-3.15%↓ Y/Y)
Research and development
$69,453K
(-1.16%↓ Y/Y)
General and
administrative
$20,718K
(-9.25%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)